

# Aequus Pharmaceuticals Inc.

10:09 18 Oct 2019

## Aequus Pharmaceuticals highlights new research showing Vistitan's effectiveness at treating glaucoma

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) updated shareholders on Friday on new research that highlights the effectiveness of the company's Vistitan product in treating glaucoma.

Results presented at the American Academy of Ophthalmology in San Francisco showed that bimatoprost 0.03%, marketed as Vistitan, is the most effective topical treatment to reduce intraocular pressure currently available for the eye disease.

Vistitan reduces the pressure inside the eyes of patients with glaucoma and was first marketed by the pharmaceutical giant Sandoz.

READ: Aequus Pharmaceuticals returns to revenue growth in second quarter  
The study was conducted by Dr Paul Harasymowycz to assess the effectiveness of the ophthalmic drug latanoprostene bunod compared to other treatments for intraocular pressure reduction after three months.

Harasymowycz and his team found that bimatoprost 0.03% is the most successful treatment to reduce pressure and mitigate the risk of glaucoma.

"In treating a disease where every millimetre of ocular pressure control is important, the data continues to support the use of Vistitan over the competition due to its effective bimatoprost 0.03% formulation," said Ian Ball, CCO of Aequus in a statement.

"This study adds to a growing body of evidence that Vistitan, the only bimatoprost 0.03% formulation currently marketed in Canada, is the most effective product available for treating glaucoma and is the cornerstone of our rapidly expanding ophthalmology franchise in Canada."

Vistitan is currently the only marketed version of 0.03% bimatoprost ophthalmic solution for glaucoma in Canada.

Shares of Aequus traded at C\$0.13 in Canada on Friday morning and US\$0.10 on OTC markets.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

**Price:** 0.08

**Market Cap:** \$6.44 m

### 1 Year Share Price Graph



### Share Information

**Code:** AQS

**Listing:** TSX-V

**52 week High Low**  
0.19 0.065

**Sector:** Pharma & Biotech

**Website:** [www.aequuspharma.ca](http://www.aequuspharma.ca)

### Company Synopsis:

*Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).